Entering the biosimilars market is essential in the long-term for any company that wishes to be a leader in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed the evolution of the firm’s injectables business at the recent J.P. Morgan Healthcare conference.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?